跳转至内容
Merck
CN

32483

伏立康唑

VETRANAL®, analytical standard

别名:

2R，3S-2-（2,4-二氟苯基）-3-（5-氟嘧啶-4-基）-1-（1H-1,2,4-三唑-1-基）丁-2-醇, UK-109496

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C16H14F3N5O
化学文摘社编号:
137234-62-9
分子量:
349.31
NACRES:
NA.24
PubChem Substance ID:
329754241
UNSPSC Code:
41116107
MDL number:
MFCD00905717

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

BCEHBSKCWLPMDN-MGPLVRAMSA-N

SMILES string

C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F

InChI

1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

grade

analytical standard

product line

VETRANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

application(s)

forensics and toxicology
pharmaceutical (small molecule)

format

neat

Quality Level

100

正在寻找类似产品? 访问 产品对比指南

相关类别

General description

Voriconazole is a second-generation triazole, and is derived from fluconazole. It has a broad and enhanced antifungal spectrum as compared to other older triazoles. It is mostly well tolerated and is available in both oral and intravenous formulations.

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Biochem/physiol Actions

伏立康唑是一种抗真菌药，可抑制麦角固醇的合成。
伏立康唑是用于治疗严重真菌感染的抗真菌药。伏立康唑通过抑制 CYP450 依赖性 14-α甾醇脱甲基酶来抑制麦角固醇合成，从而导致真菌细胞膜中的麦角固醇减少。
It has been used as one of the constituent of YPD (1% yeast extract, 2% peptone, 2% glucose) liquid media.
Voriconazole is an antifungal used to treat serious fungal infections. Voriconazole inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-a sterol demethylase resulting in a depletion of ergosterol in fungal cell membranes.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 3 - Carc. 2 - Muta. 2 - Repr. 2 - STOT RE 1 - STOT RE 2 Oral - STOT SE 2 Oral

target_organs

Eyes, Liver,Kidney

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCM3810
BCCJ3748
BCCD1754
BCBZ8761
BCBS3721V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht, Raoul, et al.
The New England Journal of Medicine, 347 (6), 408-415 (2002)
Voriconazole: a new triazole antifungal agent.
Saravolatz, Louis D., Leonard B. Johnson, and Carol A. Kauffman.
Clinical Infectious Diseases, 36 (5), 630-637 (2003)
Convergent evolution of calcineurin pathway roles in thermotolerance and virulence in Candida glabrata.
Chen, Ying-Lien, et al.
G3 (Bethesda, Md.), 2 (6), 675- 691 (2012)
Atsuko Sunada et al.
Ophthalmology, 121(10), 2059-2065 (2014-06-02)
To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Laboratory research. Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro.
Kim Vanstraelen et al.
Antimicrobial agents and chemotherapy, 58(11), 6782-6789 (2014-09-04)
Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of hypoalbuminemia (<35 g/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with voriconazole (20 samples in 13 patients) as
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持